Target

AR

Androgen receptor

Also: androgen receptor

16open trials
38trials in total
287publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Estrogen-related receptor γ functions as a novel corepressor of androgen receptor by destabilizing receptor conformation and blocking coactivator recruitment.
2 Nov 2026· Journal of biochemistry· PUBMED
Publication
Eupalinolide B targets the USP10-AR-MTHFD1 axis to sensitize castration-resistant prostate cancer to enzalutamide.
23 Oct 2026· Phytomedicine : international journal of phytotherapy and phytopharmacology· PUBMED
Publication
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors.
23 Oct 2026· Journal of experimental & clinical cancer research : CR· PUBMED
Publication
Beyond pairwise comparisons of androgen receptor signaling inhibitors in nonmetastatic castration-resistant prostate cancer.
12 Oct 2026· ESMO real world data and digital oncology· PUBMED
Trial
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
8 Oct 2026· PHASE1 · RECRUITING· CTIS
Publication
Retraction notice to "A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells" [Int. J. Biochem. Cell Biol. 41 (3) (2009) 603-614].
7 Oct 2026· The international journal of biochemistry & cell biology· PUBMED
Publication
A novel multiplex digital PCR assay for simultaneous quantification of androgen receptor amplification, mutations, and splice variants in cell-free nucleic acids from metastatic castration-resistant prostate cancer.
6 Oct 2026· The journal of liquid biopsy· PUBMED
Trial
A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
β1-AR Autoantibody-Mediated Expansion of Cardiotoxic CD4+CD28- T Cells Contributes to the Progression of Heart Failure.
1 Oct 2026· JACC. Basic to translational science· PUBMED
Publication
TRPML1 inhibitor ML-SI1 suppresses prostate cancer through dual regulation of androgen receptor and polyamine metabolism.
28 Sept 2026· Frontiers in medicine· PUBMED
Publication
Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance.
26 Sept 2026· Diagnostic pathology· PUBMED
Publication
Erratum: CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.
25 Sept 2026· American journal of cancer research· PUBMED
Preprint
AR-V7 Utilizes a Noncanonical Nuclear Localization Signal to Sustain Androgen-Independent Nuclear Import and Signaling.
24 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Dysregulation of neuronal androgen receptor signaling by divergent collaborative transcription factors in Alzheimer's disease.
22 Sept 2026· iScience· PUBMED
Publication
The AR/ARD1/DLGAP5 axis drives oncogenesis and immune evasion via PD-L1 upregulation in androgen receptor-positive triple-negative breast cancer.
16 Sept 2026· Translational research : the journal of laboratory and clinical medicine· PUBMED
Publication
Developing a Fluorescence-Based High-Throughput Screening Method for Natural Product Fractions to Identify Inhibitors of AR-V7 for Castration-Resistant Prostate Cancer.
15 Sept 2026· Pharmaceutics· PUBMED
Publication
Detection of androgen receptor (AR) splice variants across diverse prostatic and non-prostatic tumor types using the TruSight Oncology 500 (TSO500) assay.
11 Sept 2026· Human pathology· PUBMED
Publication
AR/PARP Dual-Targeting Bioactive Photosensitizer for Photo-Immunotherapy of Prostate Cancer.
9 Sept 2026· Advanced materials (Deerfield Beach, Fla.)· PUBMED
Publication
Biochanin A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancer.
1 Sept 2026· Asian journal of andrology· PUBMED
Publication
Comment on: "Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligand binding domain"-A call to validate AR signaling modulation in H874Y-expressing prostate cancer cells.
1 Sept 2026· Urologic oncology· PUBMED
Publication
Sanguinarine chloride exerts its antitumor effects on enzalutamide-resistant prostate cancer by inhibiting cell proliferation and promoting senescence via targeting AR signaling.
30 Aug 2026· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publication
Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database.
28 Aug 2026· Japanese journal of clinical oncology· PUBMED
Publication
Erratum: The RNA helicase DDX17 enhances androgen receptor stability by interacting with the E3 ubiquitin ligase SPOP in prostate cancer.
27 Aug 2026· Translational andrology and urology· PUBMED
Publication
Neutropenia events with androgen receptor pathway inhibitor-containing versus control therapies in prostate cancer patients: a systematic review and meta-analysis.
22 Aug 2026· BMC cancer· PUBMED
Publication
Cotinine enhances androgen receptor stability and promotes androgen-dependent proliferation in prostate cancer cells: An in vitro study.
19 Aug 2026· Archives of biochemistry and biophysics· PUBMED
Trial
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
18 Aug 2026· PHASE2 · RECRUITING· CTGOV
Publication
Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis.
18 Aug 2026· Clinical genitourinary cancer· PUBMED
Publication
Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer.
18 Aug 2026· Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners· PUBMED
Publication
Utilization patterns of second-generation androgen receptor pathway inhibitors as first-line therapy for prostate cancer in the United States.
14 Aug 2026· Prostate cancer and prostatic diseases· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error